Market Research Logo

Migraine - Pipeline Review, H1 2018

Migraine - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H1 2018, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 13, 12, 15, 27, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Migraine - Overview 6
Migraine - Therapeutics Development 7
Migraine - Therapeutics Assessment 19
Migraine - Companies Involved in Therapeutics Development 29
Migraine - Drug Profiles 49
Migraine - Dormant Projects 195
Migraine - Discontinued Products 199
Migraine - Product Development Milestones 200
Appendix 210
List of Tables
Number of Products under Development for Migraine, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Migraine - Pipeline by 4P Therapeutics LLC, H1 2018
Migraine - Pipeline by Abide Therapeutics Inc, H1 2018
Migraine - Pipeline by Achelios Therapeutics Inc, H1 2018
Migraine - Pipeline by Acorda Therapeutics Inc, H1 2018
Migraine - Pipeline by Alder Biopharmaceuticals Inc, H1 2018
Migraine - Pipeline by Allergan Plc, H1 2018
Migraine - Pipeline by Amgen Inc, H1 2018
Migraine - Pipeline by Aralez Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Astellas Pharma Inc, H1 2018
Migraine - Pipeline by Avanir Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Axsome Therapeutics Inc, H1 2018
Migraine - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Migraine - Pipeline by BioHealthonomics Inc, H1 2018
Migraine - Pipeline by Blackthorn Therapeutics Inc, H1 2018
Migraine - Pipeline by Charleston Laboratories Inc, H1 2018
Migraine - Pipeline by Corium International Inc, H1 2018
Migraine - Pipeline by Crossject SA, H1 2018
Migraine - Pipeline by Eli Lilly and Co, H1 2018
Migraine - Pipeline by Heptares Therapeutics Ltd, H1 2018
Migraine - Pipeline by Impel NeuroPharma Inc, H1 2018
Migraine - Pipeline by InKemia IUCT Group SA, H1 2018
Migraine - Pipeline by InStar Technologies AS, H1 2018
Migraine - Pipeline by Insys Therapeutics Inc, H1 2018
Migraine - Pipeline by IntelGenx Corp, H1 2018
Migraine - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Klaria Pharma Holding AB, H1 2018
Migraine - Pipeline by Medy-Tox Inc, H1 2018
Migraine - Pipeline by Merck & Co Inc, H1 2018
Migraine - Pipeline by NAL Pharmaceuticals Ltd, H1 2018
Migraine - Pipeline by Pharmaleads SA, H1 2018
Migraine - Pipeline by Promius Pharma LLC, H1 2018
Migraine - Pipeline by Q BioMed Inc, H1 2018
Migraine - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H1 2018
Migraine - Pipeline by Suda Ltd, H1 2018
Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Migraine - Pipeline by TheraJect Inc, H1 2018
Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018
Migraine - Pipeline by Trevena Inc, H1 2018
Migraine - Pipeline by Trigemina Inc, H1 2018
Migraine - Pipeline by TrioxBio Inc, H1 2018
Migraine - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018
Migraine - Pipeline by Xenon Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Xoc Pharmaceuticals Inc, H1 2018
Migraine - Pipeline by Zosano Pharma Corp, H1 2018
Migraine - Dormant Projects, H1 2018
Migraine - Dormant Projects, H1 2018 (Contd..1), H1 2018
Migraine - Dormant Projects, H1 2018 (Contd..2), H1 2018
Migraine - Dormant Projects, H1 2018 (Contd..3), H1 2018
Migraine - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Migraine, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report